Cargando…

Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence

BACKGROUND: Among men and women diagnosed with colorectal cancer (CRC), 20–50% will develop a cancer recurrence. Cancer recurrences are not routinely captured by most population-based registries; however, linkage across Danish registries allows for the development of predictive models to detect recu...

Descripción completa

Detalles Bibliográficos
Autores principales: Collin, Lindsay J, Riis, Anders H, MacLehose, Richard F, Ahern, Thomas P, Erichsen, Rune, Thorlacius-Ussing, Ole, Lash, Timothy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007499/
https://www.ncbi.nlm.nih.gov/pubmed/32099477
http://dx.doi.org/10.2147/CLEP.S230314
_version_ 1783495325259923456
author Collin, Lindsay J
Riis, Anders H
MacLehose, Richard F
Ahern, Thomas P
Erichsen, Rune
Thorlacius-Ussing, Ole
Lash, Timothy L
author_facet Collin, Lindsay J
Riis, Anders H
MacLehose, Richard F
Ahern, Thomas P
Erichsen, Rune
Thorlacius-Ussing, Ole
Lash, Timothy L
author_sort Collin, Lindsay J
collection PubMed
description BACKGROUND: Among men and women diagnosed with colorectal cancer (CRC), 20–50% will develop a cancer recurrence. Cancer recurrences are not routinely captured by most population-based registries; however, linkage across Danish registries allows for the development of predictive models to detect recurrence. Successful application of such models in population-based settings requires validation against a gold standard to ensure the accuracy of recurrence identification. OBJECTIVE: We apply a recently developed validation study design for prospectively collected validation data to validate predicted CRC recurrences against gold standard diagnoses from medical records in an actively followed cohort of CRC patients in Denmark. METHODS: We use a Bayesian monitoring framework, traditionally used in clinical trials, to iteratively update classification parameters (positive and negative predictive values, and sensitivity and specificity) in an adaptive validation substudy design. This design allows determination of the sample size necessary to estimate the corresponding parameters and to identify when validation efforts can cease based on predefined criteria for parameter values and levels of precision. RESULTS: Among 355 men and women diagnosed with CRC in Denmark and actively followed semi-annually, there were 63 recurrences diagnosed by active follow-up and 70 recurrences identified by a predictive algorithm. The adaptive validation design met stopping criteria for the classification parameters after 120 patients had their recurrence information validated. This stopping point yielded parameter estimates for the classification parameters similar to those obtained when the entire cohort was validated, with 66% less patients needed for the validation study. CONCLUSION: In this proof of concept application of the adaptive validation study design for outcome misclassification, we demonstrated the ability of the method to accurately determine when sufficient validation data have been collected. This method serves as a novel validation substudy design for prospectively collected data with simultaneous implementation of a validation study.
format Online
Article
Text
id pubmed-7007499
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70074992020-02-25 Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence Collin, Lindsay J Riis, Anders H MacLehose, Richard F Ahern, Thomas P Erichsen, Rune Thorlacius-Ussing, Ole Lash, Timothy L Clin Epidemiol Original Research BACKGROUND: Among men and women diagnosed with colorectal cancer (CRC), 20–50% will develop a cancer recurrence. Cancer recurrences are not routinely captured by most population-based registries; however, linkage across Danish registries allows for the development of predictive models to detect recurrence. Successful application of such models in population-based settings requires validation against a gold standard to ensure the accuracy of recurrence identification. OBJECTIVE: We apply a recently developed validation study design for prospectively collected validation data to validate predicted CRC recurrences against gold standard diagnoses from medical records in an actively followed cohort of CRC patients in Denmark. METHODS: We use a Bayesian monitoring framework, traditionally used in clinical trials, to iteratively update classification parameters (positive and negative predictive values, and sensitivity and specificity) in an adaptive validation substudy design. This design allows determination of the sample size necessary to estimate the corresponding parameters and to identify when validation efforts can cease based on predefined criteria for parameter values and levels of precision. RESULTS: Among 355 men and women diagnosed with CRC in Denmark and actively followed semi-annually, there were 63 recurrences diagnosed by active follow-up and 70 recurrences identified by a predictive algorithm. The adaptive validation design met stopping criteria for the classification parameters after 120 patients had their recurrence information validated. This stopping point yielded parameter estimates for the classification parameters similar to those obtained when the entire cohort was validated, with 66% less patients needed for the validation study. CONCLUSION: In this proof of concept application of the adaptive validation study design for outcome misclassification, we demonstrated the ability of the method to accurately determine when sufficient validation data have been collected. This method serves as a novel validation substudy design for prospectively collected data with simultaneous implementation of a validation study. Dove 2020-02-03 /pmc/articles/PMC7007499/ /pubmed/32099477 http://dx.doi.org/10.2147/CLEP.S230314 Text en © 2020 Collin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Collin, Lindsay J
Riis, Anders H
MacLehose, Richard F
Ahern, Thomas P
Erichsen, Rune
Thorlacius-Ussing, Ole
Lash, Timothy L
Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence
title Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence
title_full Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence
title_fullStr Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence
title_full_unstemmed Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence
title_short Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence
title_sort application of the adaptive validation substudy design to colorectal cancer recurrence
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007499/
https://www.ncbi.nlm.nih.gov/pubmed/32099477
http://dx.doi.org/10.2147/CLEP.S230314
work_keys_str_mv AT collinlindsayj applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence
AT riisandersh applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence
AT maclehoserichardf applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence
AT ahernthomasp applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence
AT erichsenrune applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence
AT thorlaciusussingole applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence
AT lashtimothyl applicationoftheadaptivevalidationsubstudydesigntocolorectalcancerrecurrence